TMX Newsfile Cannabis Ancillary Service Provider News Releases

Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

Fri, 17 Jul 2026 07:50:00 -0400

Rhelion Life Sciences reflects the Company's evolution into a sharpened focused, science-driven life sciences platform dedicated to psychedelic drug discovery, development, and innovationToronto, Ontario--(Newsfile Corp. - July 17, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") is pleased to announce that it will be changing its corporate name to Rhelion Life Sciences Corp ("Rhelion"), marking the beginning of an exciting new chapter for the...

Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Thu, 16 Jul 2026 08:03:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...

Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg

Wed, 08 Jul 2026 08:00:00 -0400

Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths to deliver the widest standardized dosing range available from any natural psilocybin drug candidate, every strength produced using the same proprietary extraction and stabilization methods.Toronto, Ontario--(Newsfile Corp. - July 8, 2026) - Red Light Holland Corp. (CSE:...

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Tue, 07 Jul 2026 08:12:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss managementToronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade...

Quinsam Grants Options

Mon, 15 Jun 2026 08:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION BY ANY UNITED STATES NEWS DISTRIBUTION SERVICEToronto, Ontario--(Newsfile Corp. - June 15, 2026) - Quinsam Capital Corporation (CSE: QCA) ("Quinsam" or the "Company") is announcing that it has granted an aggregate of 3,440,000 stock options ("Options") to directors and officers of the Company pursuant to the Company's stock option plan. The Options vest on the date of grant and entitle the holder to purchase common shares of the...

Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan Portfolio

Fri, 12 Jun 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) (the "Company" or "Britannia") is pleased to announce that it has completed a strategic investment of approximately $5.3 million in a portfolio of performing commercial equipment loans (the "Investment") on highly opportunistic terms. The Investment represents the continued execution of the Company's asset-backed lending strategy and meaningfully expands the Company's base of recurring, high-return...

CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026

Tue, 09 Jun 2026 19:32:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company's news release dated June 9, 2026. The appointment of Mr. Emes to the Company's Board of Directors is effective June 9, 2026, not April 3, 2025 as previously stated. All other information contained in the news release...

Entheon Announces Change of Directors

Tue, 09 Jun 2026 16:26:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes to the Company's Board of Directors, effective April 3, 2025.Mr. Emes is a seasoned entrepreneur with extensive experience in capital markets, corporate development and investor relations. He is the Co-Founder of Black Swan Solutions Inc., where he has worked with over 80 clients across various...

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Mon, 08 Jun 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived...